CHF medications: Difference between revisions
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
| (-)<br/> | | (-)<br/> | ||
| -<br/> | | -<br/> | ||
| -+<br/> | | -/+<br/> | ||
|- | |- | ||
| hydral100 | | hydral100 | ||
| Line 24: | Line 24: | ||
| ~<br/> | | ~<br/> | ||
| -<br/> | | -<br/> | ||
| +-<br/> | | +/-<br/> | ||
| ++<br/> | | ++<br/> | ||
|- | |- | ||
| Line 31: | Line 31: | ||
| --<br/> | | --<br/> | ||
| ++<br/> | | ++<br/> | ||
| -+<br/> | | -/+<br/> | ||
| +-<br/> | | +/-<br/> | ||
|- | |- | ||
| ACEI | | ACEI | ||
| Line 38: | Line 38: | ||
| -<br/> | | -<br/> | ||
| -<br/> | | -<br/> | ||
| +-<br/> | | +/-<br/> | ||
| +<br/> | | +<br/> | ||
|- | |- | ||
| Line 45: | Line 45: | ||
| ~<br/> | | ~<br/> | ||
| --<br/> | | --<br/> | ||
| +-<br/> | | +/-<br/> | ||
| ++<br/> | | ++<br/> | ||
|} | |} | ||
Revision as of 18:45, 9 March 2011
| Agent |
RA | RCW | SVR | BP | CO |
| Isordil60 | - |
- |
(-) |
- |
-/+ |
| hydral100 | ~ |
~ |
- |
+/- |
++ |
| hy (MR/AI) | - |
-- |
++ |
-/+ |
+/- |
| ACEI | - |
- |
- |
+/- |
+ |
| Minoxidil | ~ |
~ |
-- |
+/- |
++ |
Carvedilol: decreases mortality 67%
Digoxin: decrease syx/hospitaliz.
Aldactone in Class IV dec mortality
Isordil: cor. VD; +BP if ischemia
ISDN/HYDRA. decreased mortality in CHF.
ACEI GREAT mortality benefit.
Target Doses
Hydralazine: 100 TID start 25
Isordil: 60-80 TID
Captopril: 100 TID start 12.5
Lisinopril/enalapril: 10 bid class II/III
20 bid class IV
Carvedilol 25 BID; 50 BID if >80kg
Digoxin: varies
Spironolactone 25-50 qd
Enalapril 1.25mg IV
Nitroglycerin (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 10-200ug/min)
Nitroprusside (Initial dose 5-10ug/min, increased every 3-5 minute to dose range 5-400ug/min)
- Consider when need afterload reduction
See Also
Cards: Congestive Heart Failure (CHF)